Drug developer Labopharm Inc. said the Food and Drug Administration sent the company a second approvable letter, saying data on its proposed once-daily formulation of the painkiller tramadol was not sufficient.
Internet NewsShare and Enjoy:These icons link to social bookmarking sites where readers can share and discover new web pages.
Original post by Associated Press and software by Elliott Back
